Kintiga unifies MAP Patient Access, AxTalis, and SKC with one name and one vision: To be the indispensable European strategic partner for health technology developers, streamlining patient access to life-changing treatments through expert guidance, innovative tools, and impeccable delivery.
For a deeper dive into the evolving EU HTA landscape, our whitepaper provides a comprehensive analysis of the regulation’s impact, strategic considerations for market access, and practical insights for navigating the new framework.
Our exclusive white paper provides a comprehensive analysis to derive key considerations for the strategic challenges for gene therapies in Germany, with a focus on pricing and reimbursement
With our longstanding AMNOG-expertise we support DiGA-providers with a customized market access strategy – all the way from the development of the value story to successful price negotiations.
